Mass Spectrometry Offers High-Throughput Screening
In this video, Dr. Jonathan Wingfield of AstraZeneca talks about a new mass spectrometry prototype. Mass spectrometry has the ability to screen samples very quickly in an extremely clean way, thus there are fewer artifacts. It can often be done as a direct measurement of substrate to product conversion, which is great as there won’t be the need to buy extra reagents and labels, thereby saving costs. If the cost increases, it would mean reduced number of samples.
The Rapidfire series marketed by Agilent are considered to be the state-of-the art instrument for high-speed screening as they use a simple solid phase extraction methodology, which allows faster sample processing (8-10 seconds per sample). However, even that speed is not fast enough. AstraZeneca has entered into collaboration to push forward the boundaries of high-speed mass spectrometry. Acoustics has not been used much in the field of electrospray mass spectrometry, but AstraZeneca has started incorporating it even though it is still in prototype phase. Acoustics provides the advantages of high-throughput and low sample handling. AstraZeneca has screened nearly 5 million samples so far with this new platform, which was not possible in the past. It may take about 18 months before this platform is commercialized. The company anticipates its use in the biochemical screening domain. The prototype will be showcased at PITTCON Conference and Expo.
Run Time – 3:33min